Cargando…
Tolerance to neurochemical and behavioral effects of the hallucinogen 25I-NBOMe
RATIONALE: 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe) is a potent serotonin 5-HT(2A/2C) receptor agonist with hallucinogenic activity. There is no data on the 25I-NBOMe effect on brain neurotransmission and animal performance after chronic administration. OBJECTIVES: We exami...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292280/ https://www.ncbi.nlm.nih.gov/pubmed/34032876 http://dx.doi.org/10.1007/s00213-021-05860-5 |
_version_ | 1783724798397906944 |
---|---|
author | Herian, Monika Skawski, Mateusz Wojtas, Adam Sobocińska, Małgorzata K. Noworyta, Karolina Gołembiowska, Krystyna |
author_facet | Herian, Monika Skawski, Mateusz Wojtas, Adam Sobocińska, Małgorzata K. Noworyta, Karolina Gołembiowska, Krystyna |
author_sort | Herian, Monika |
collection | PubMed |
description | RATIONALE: 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe) is a potent serotonin 5-HT(2A/2C) receptor agonist with hallucinogenic activity. There is no data on the 25I-NBOMe effect on brain neurotransmission and animal performance after chronic administration. OBJECTIVES: We examined the effect of a 7-day treatment with 25I-NBOMe (0.3 mg/kg/day) on neurotransmitters’ release and rats’ behavior in comparison to acute dose. METHODS: Changes in dopamine (DA), serotonin (5-HT), acetylcholine (ACh), and glutamate release were studied using microdialysis in freely moving rats. The hallucinogenic activity was measured in the wet dog shake (WDS) test. The animal locomotion was examined in the open field (OF) test, short-term memory in the novel object recognition (NOR) test. The anxiogenic/anxiolytic properties of the drug were tested using the light/dark box (LDB) test. RESULTS: Repeated administration of 25I-NBOMe decreased the response to a challenge dose of DA, 5-HT, and glutamatergic neurons in the frontal cortex as well as weakened the hallucinogenic activity in comparison to acute dose. In contrast, striatal and accumbal DA and 5-HT release and accumbal but not striatal glutamate release in response to the challenge dose of 25I-NBOMe was increased in comparison to acute treatment. The ACh release was increased in all brain regions. Behavioral tests showed a motor activity reduction and memory deficiency in comparison to a single dose and induction of anxiety after the drug’s chronic and acute administration. CONCLUSIONS: Our findings suggest that multiple injections of 25I-NBOMe induce tolerance to hallucinogenic activity and produce alterations in neurotransmission. 25I-NBOMe effect on short-term memory, locomotor function, and anxiety seems to be the result of complex interactions between neurotransmitter pathways. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00213-021-05860-5. |
format | Online Article Text |
id | pubmed-8292280 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-82922802021-07-23 Tolerance to neurochemical and behavioral effects of the hallucinogen 25I-NBOMe Herian, Monika Skawski, Mateusz Wojtas, Adam Sobocińska, Małgorzata K. Noworyta, Karolina Gołembiowska, Krystyna Psychopharmacology (Berl) Original Investigation RATIONALE: 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe) is a potent serotonin 5-HT(2A/2C) receptor agonist with hallucinogenic activity. There is no data on the 25I-NBOMe effect on brain neurotransmission and animal performance after chronic administration. OBJECTIVES: We examined the effect of a 7-day treatment with 25I-NBOMe (0.3 mg/kg/day) on neurotransmitters’ release and rats’ behavior in comparison to acute dose. METHODS: Changes in dopamine (DA), serotonin (5-HT), acetylcholine (ACh), and glutamate release were studied using microdialysis in freely moving rats. The hallucinogenic activity was measured in the wet dog shake (WDS) test. The animal locomotion was examined in the open field (OF) test, short-term memory in the novel object recognition (NOR) test. The anxiogenic/anxiolytic properties of the drug were tested using the light/dark box (LDB) test. RESULTS: Repeated administration of 25I-NBOMe decreased the response to a challenge dose of DA, 5-HT, and glutamatergic neurons in the frontal cortex as well as weakened the hallucinogenic activity in comparison to acute dose. In contrast, striatal and accumbal DA and 5-HT release and accumbal but not striatal glutamate release in response to the challenge dose of 25I-NBOMe was increased in comparison to acute treatment. The ACh release was increased in all brain regions. Behavioral tests showed a motor activity reduction and memory deficiency in comparison to a single dose and induction of anxiety after the drug’s chronic and acute administration. CONCLUSIONS: Our findings suggest that multiple injections of 25I-NBOMe induce tolerance to hallucinogenic activity and produce alterations in neurotransmission. 25I-NBOMe effect on short-term memory, locomotor function, and anxiety seems to be the result of complex interactions between neurotransmitter pathways. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00213-021-05860-5. Springer Berlin Heidelberg 2021-05-25 2021 /pmc/articles/PMC8292280/ /pubmed/34032876 http://dx.doi.org/10.1007/s00213-021-05860-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Investigation Herian, Monika Skawski, Mateusz Wojtas, Adam Sobocińska, Małgorzata K. Noworyta, Karolina Gołembiowska, Krystyna Tolerance to neurochemical and behavioral effects of the hallucinogen 25I-NBOMe |
title | Tolerance to neurochemical and behavioral effects of the hallucinogen 25I-NBOMe |
title_full | Tolerance to neurochemical and behavioral effects of the hallucinogen 25I-NBOMe |
title_fullStr | Tolerance to neurochemical and behavioral effects of the hallucinogen 25I-NBOMe |
title_full_unstemmed | Tolerance to neurochemical and behavioral effects of the hallucinogen 25I-NBOMe |
title_short | Tolerance to neurochemical and behavioral effects of the hallucinogen 25I-NBOMe |
title_sort | tolerance to neurochemical and behavioral effects of the hallucinogen 25i-nbome |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292280/ https://www.ncbi.nlm.nih.gov/pubmed/34032876 http://dx.doi.org/10.1007/s00213-021-05860-5 |
work_keys_str_mv | AT herianmonika tolerancetoneurochemicalandbehavioraleffectsofthehallucinogen25inbome AT skawskimateusz tolerancetoneurochemicalandbehavioraleffectsofthehallucinogen25inbome AT wojtasadam tolerancetoneurochemicalandbehavioraleffectsofthehallucinogen25inbome AT sobocinskamałgorzatak tolerancetoneurochemicalandbehavioraleffectsofthehallucinogen25inbome AT noworytakarolina tolerancetoneurochemicalandbehavioraleffectsofthehallucinogen25inbome AT gołembiowskakrystyna tolerancetoneurochemicalandbehavioraleffectsofthehallucinogen25inbome |